Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Abbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of Rheumatology Annual Scientific Meeting


      News provided by

      Abbott

      02 Nov, 2011, 10:00 GMT

      Share this article

      Share this article


      ABBOTT PARK, Illinois, November 2, 2011 /PRNewswire/ --

      - Data Highlight Efficacy, Safety and Health Outcomes

      Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest research findings on HUMIRA® (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.  The presentations include data on rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS) and spondyloarthritis (SpA), as well as health economics research.

      "At this year's ACR, taking place in our home town of Chicago, researchers will share a broad spectrum of compelling data for HUMIRA across approved and investigational indications," said John Leonard, M.D., senior vice president, Global Pharmaceutical Research and Development, Abbott.  "These studies underscore our commitment to advancing treatment for rheumatologic diseases and meeting the needs of patients, physicians and payors around the world."

      Presentation Highlights

      Abbott data being presented at ACR include the first presentation of results from ABILITY-1, the first Phase 3 study to evaluate an anti-tumor necrosis factor medication (anti-TNF) in patients with non-radiographic axial spondyloarthritis.  These data were selected for an oral presentation on November 8.  

      The company also will present clinical and patient-reported outcomes from OPTIMA, the first global prospective trial using a treat-to-target philosophy in the treatment of moderate to severe rheumatoid arthritis.  Treat to target is focused on achieving a clearly defined treatment goal within a set duration of time and adjusting the treatment if the target is not met.  In OPTIMA, the treatment goal was a composite primary endpoint of low disease activity score (DAS28<3.2) and no radiographic progression (change from baseline in modified total Sharp score of less than or equal to 0.5).

      Additionally, Abbott is presenting data from among the longest open-label extension studies in RA: 10-year data from the open-label extension of the DE019 trial of patients with moderate to severe long-standing RA and eight-year data from the open-label extension of the PREMIER trial of patients with early moderate to severe RA.  Abbott also will present five-year results from the open-label extension of the ATLAS study.  ATLAS is a Phase 3, multicenter, double-blind trial of patients with active AS randomized to HUMIRA 40 mg every other week or placebo for 24 weeks followed by an open-label extension up to five years.

      A comprehensive list of ACR abstracts is available at http://www.rheumatology.org.

      Identified below are some HUMIRA abstracts of interest (all times are CST):

      Rheumatoid Arthritis

      Study Related to Clinical and Radiographic Implications of Time to Treatment Response in Early Rheumatoid Arthritis Patients with Baseline Levels of Disease Activity Reflective of a Clinical Practice Setting; E. Keystone, et al

      • Abstract 417; Poster Session; November 6, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Analysis of Genetic Influence of HLA-DRB1, IL4R and FcyRIIb on Radiographic Responses to Methotrexate Monotherapy or Adalimumab Plus Methotrexate Through 26 Weeks in Patients with Early Rheumatoid Arthritis; A. Skapenko, et al

      • Abstract 154; Poster Session; November 6, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Eight-Year Results of an Open-Label Extension of a Phase 3 Trial Related to Initial Combination Therapy with Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis; F. Breedveld, et al

      • Abstract 1231; Poster Session; November 7, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Study Related to Baseline Levels of the Inflammatory Biomarker C-Reactive Protein Correlation with Magnetic Resonance Imaging Measures of Synovitis at Baseline and After 26 Weeks of Treatment in Patients with Early Rheumatoid Arthritis; C. Peterfy, et al

      • Abstract 1612; Oral Abstract Session; November 7, 2011; 2:45 p.m.; Location: W 474 A

      Study Related to Outcomes and Predictors in Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate, Methotrexate Alone or Methotrexate Plus Subsequent Adalimumab; J. Smolen, et al

      • Abstract 1698; Oral Abstract Session; November 7, 2011; 5:15 p.m.; Location: W 375 C

      Results of a Phase 4, Double-Blind, Placebo-Controlled Trial Related to Withdrawal of Adalimumab in Early Rheumatoid Arthritis Patients Who Attained Stable Low Disease Activity with Adalimumab Plus Methotrexate; A. Kavanaugh, et al

      • Abstract 1699; Oral Abstract Session; November 7, 2011; 5:30 p.m.; Location: W 375 C

      Final 10-Year Results of an Open-Label Extension of a Phase 3 Trial Related to Initial Combination Therapy with Adalimumab Plus Methotrexate in Patients with Long-standing RA; E. Keystone, et al

      • Abstract 2228; Poster Session; November 8, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Phase 3b and Post-Marketing Observational Study Related to Safety and Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis During More Than Five Years of Therapy; G. Burmester, et al

      • Abstract 2216; Poster Session; November 8, 2011; 9 a.m.  - 11 a.m.; Location: Poster Hall

      Juvenile Idiopathic Arthritis

      Study Related to Long-Term Efficacy and Safety of Adalimumab for up to Six Years in Patients with Juvenile Idiopathic Arthritis; D. Lovell, et al

      • Abstract 265; Poster Session; November 6, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Ankylosing Spondylitis/Spondyloarthritis

      Five-Year Results Related to Improvement of Spinal Mobility, Physical Function and Quality of Life in Patients with Ankylosing Spondylitis; D. van der Heijde, et al

      • Abstract 535; Poster Session; November 6, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Results from a Phase 3 Study Related to Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis; J. Sieper, et al

      • Abstract 2486A; Oral Abstract Session; November 8, 2011; 2:30 p.m.; Location: W 475 A

      Health and Economic Outcomes

      Study Related to The Impact of Disease Duration on Work Status in Patients with Rheumatoid Arthritis; L. Harrold, et al

      • Abstract 108; Poster Session; November 6, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Impact of Juvenile Idiopathic Arthritis on Parents' Work Absences; R. Rasu, et al

      • Abstract 259; Poster Session; November 6, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Work Absences and Costs Associated with Rheumatoid Arthritis: A Comparison between Employees with and without Rheumatoid Arthritis in a U.S. Population; R. Brook, et al

      • Abstract 913; Poster Session; November 7, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Study Related to Effect of Adalimumab on Function, Health-Related Quality of Life, Work Productivity and Daily Activities in Patients with Non-Radiographic Axial Spondyloarthritis; W. Maksymowych, et al

      • Abstract 1312; Poster Session; November 7, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Validation of the Patient Acceptable Work State: Establishing Thresholds for Patient-Reported Outcomes in a Longitudinal, Observational Study in Patients with Ankylosing Spondylitis; W. Maksymowych, et al

      • Abstract 1326; Poster Session; November 7, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      Results from a 26-Week Analysis of Combination Therapy with Adalimumab+Methotrexate Related to Work Ability, Physical Function, Fatigue and Other Patient-Reported Outcomes in Early Rheumatoid Arthritis; R. van Vollenhoven, et al

      • Abstract 2189; Poster Session: November 8, 2011; 9 a.m. - 11 a.m.; Location: Poster Hall

      About HUMIRA

      HUMIRA (adalimumab) is a prescription medicine used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults.  It may prevent future damage to bones and joints and may help with the ability to perform daily activities.

      HUMIRA is used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children 4 years of age and older.

      HUMIRA is used to reduce the signs and symptoms of ankylosing spondylitis in adults.

      HUMIRA is used alone or with certain other medicines to reduce the signs and symptoms of psoriatic arthritis in adults.  It may prevent further damage to bones and joints and may help with the ability to perform daily activities.

      HUMIRA is not approved for the treatment of spondyloarthritides other than ankylosing spondylitis and psoriatic arthritis.  

      Important Safety Information

      HUMIRA is a TNF blocker that affects the immune system and can lower the ability to fight infections.

      People treated with HUMIRA are at an increased risk for developing serious infections that may lead to hospitalization or death.  Reported serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body.  People should be tested for TB before HUMIRA use and monitored for signs and symptoms of TB during therapy.  People at risk of TB may be treated with medicine for TB. Treatment with HUMIRA should not be started in a person with an active infection, unless approved by a doctor.  HUMIRA should be stopped if a person develops a serious infection.

      For people taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase.  Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma.  This type of cancer often results in death.

      Other possible serious side effects with HUMIRA include hepatitis B infection in carriers of the virus, allergic reactions, nervous system problems, blood problems, certain immune reactions, including a lupus-like syndrome, liver problems and new or worsening heart failure or psoriasis.  The use of HUMIRA with anakinra or abatacept is not recommended.  People using HUMIRA should not receive live vaccines.

      Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), headaches, rash and nausea.

      As with any treatment program, the benefits and risks of HUMIRA should be carefully considered before starting therapy.

      About Abbott

      Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

      Abbott's news releases and other information are available on the company's website at http://www.abbott.com.

      Modal title

      Also from this source

      Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

      Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

      Abbott, a global healthcare leader, announced today that the Cologuard Plus® test has received CE Mark under the European Union's In Vitro Diagnostic ...

      Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

      Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

      Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose–ketone sensing technology...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Trade Show News

      Trade Show News

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.